Novartis’s Pipeline Just Lost Two Big Bets – Moby THE GIST
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Drug development can turn billions into zero surprisingly quickly. Novartis just got that reminder twice, with two major Phase III failures sending its shares toward one of their ugliest sessions in decades.
WHAT HAPPENED
Novartis shares dropped around 9% after the Swiss pharmaceutical giant reported disappointing Phase III results for del-desiran, an experimental treatment for myotonic dystrophy type 1.
The HARBOR study failed to demonstrate a statistically significant improvement over placebo on its primary endpoint, video hand opening time, a measure of the muscle stiffness suffered by patients with the rare progressive disorder. That would have hurt on its own.
It hurt much more because del-desiran came from Novartis’s $12 billion acquisition of Avidity Biosciences, completed in February. The deal brought three late-stage neuromuscular programs and an antibody oligonucleotide conjugate platform that management hoped could produce multiple new medicines before 2030.
Del-desiran was the most advanced test of that investment.
There were some positives buried in the data. The treatment showed signs of clinical activity across secondary endpoints and exploratory analyses, while its safety profile was broadly consistent with previous findings. Novartis will now analyze the complete dataset and discuss potential next steps with regulators.
But investors did not hang around for the footnotes.
Shares sank roughly 9%, wiping billions from Novartis’s market capitalization and putting the stock on course for one of its worst trading days on record. And the timing was brutal.
The previous trading day, Novartis shares had already fallen more than 3% after another major drug candidate, pelacarsen, failed its Phase III Lp(a)HORIZON study.
Pelacarsen successfully lowered levels of lipoprotein(a), an inherited cardiovascular risk factor affecting roughly one in five people. Unfortunately, lowering the biomarker did not translate into the result that matters most: significantly fewer cardiovascular deaths, heart attacks, strokes and urgent coronary procedures compared with placebo.
The drug had been viewed as a potential blockbuster, with peak annual sales expectations reaching several billion dollars.
Two pivotal failures in rapid succession suddenly turned a pipeline packed with promise into a much harder valuation puzzle.
WHY IT MATTERS
Big pharma companies are basically running relay races against patent cliffs.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Today’s blockbuster eventually loses exclusivity. Cheap competition arrives. Revenue falls. So companies like Novartis constantly need the next generation of medicines ready to pick up the baton. That’s why these failures matter far beyond two experimental drugs.
Novartis is targeting 5% to 6% annual sales growth between 2025 and 2030, a goal it reiterated despite the latest setback. To hit that target and keep growing afterward, it needs its pipeline to produce multiple large products.
Pelacarsen and del-desiran were supposed to help.
The del-desiran failure is particularly uncomfortable because Novartis paid $12 billion for Avidity only months ago. The acquisition was pitched as a way to strengthen the late-stage pipeline and open multi-billion-dollar opportunities in genetic neuromuscular diseases.
Paying billions for science that later fails is not unusual in pharma. Clinical development is brutal precisely because even promising drugs can collapse at Phase III. But timing changes perception.
When a flagship asset fails shortly after a major acquisition, investors stop asking only whether the drug works. They start asking whether management paid too much, whether the due diligence was good enough and whether the remaining acquired assets deserve the same confidence.
Pelacarsen creates a different headache. Its failure raises questions about whether reducing Lp(a) itself will reliably reduce cardiovascular events, potentially affecting an entire field being pursued by rivals including Amgen and Eli Lilly.
So Novartis managed to lose one company-specific bet and shake confidence in a broader therapeutic idea almost simultaneously. That’s some efficient bad news.
WHAT’S NEXT
Novartis still has plenty of shots on goal.
The other Avidity programs continue moving forward, while remibrutinib recently delivered positive Phase III results in relapsing multiple sclerosis. The company has also kept its 5% to 6% sales-growth target through 2030. But investors will now apply a much bigger discount to promises about the pipeline.
The immediate questions are whether del-desiran has any viable regulatory path left, what the full pelacarsen data reveal and whether the remaining Avidity assets can justify the $12 billion price tag. The bigger question lands on CEO Vas Narasimhan.
Novartis has used acquisitions and pipeline investment to build the growth engines meant to carry it beyond today’s blockbusters. Two Phase III failures do not destroy that strategy.
They do make the next wins considerably less optional.